2341 related articles for article (PubMed ID: 31101865)
1. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion.
Friedmann Angeli JP; Krysko DV; Conrad M
Nat Rev Cancer; 2019 Jul; 19(7):405-414. PubMed ID: 31101865
[TBL] [Abstract][Full Text] [Related]
2. How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.
Li J; Stanger BZ
Cancer Res; 2020 Oct; 80(19):4037-4041. PubMed ID: 32554552
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic ferroptosis and where to find it?
Demuynck R; Efimova I; Naessens F; Krysko DV
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903554
[TBL] [Abstract][Full Text] [Related]
4. Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance.
Long KB; Collier AI; Beatty GL
Mol Immunol; 2019 Jun; 110():3-12. PubMed ID: 29273393
[TBL] [Abstract][Full Text] [Related]
5. Ferroptosis is an effective strategy for cancer therapy.
Khan A; Huo Y; Guo Y; Shi J; Hou Y
Med Oncol; 2024 Apr; 41(5):124. PubMed ID: 38652406
[TBL] [Abstract][Full Text] [Related]
6. Metabolic reprogramming, autophagy, and ferroptosis: Novel arsenals to overcome immunotherapy resistance in gastrointestinal cancer.
Wang X; Zhou L; Wang H; Chen W; Jiang L; Ming G; Wang J
Cancer Med; 2023 Nov; 12(21):20573-20589. PubMed ID: 37860928
[TBL] [Abstract][Full Text] [Related]
7. Overcoming cancer chemotherapy resistance by the induction of ferroptosis.
Wang Y; Wu X; Ren Z; Li Y; Zou W; Chen J; Wang H
Drug Resist Updat; 2023 Jan; 66():100916. PubMed ID: 36610291
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.
Roesch A; Paschen A; Landsberg J; Helfrich I; Becker JC; Schadendorf D
Eur J Cancer; 2016 May; 59():109-112. PubMed ID: 27023049
[TBL] [Abstract][Full Text] [Related]
9. Targeting the tumour microenvironment in platinum-resistant ovarian cancer.
Cummings M; Freer C; Orsi NM
Semin Cancer Biol; 2021 Dec; 77():3-28. PubMed ID: 33607246
[TBL] [Abstract][Full Text] [Related]
10. The great escape: tumour cell plasticity in resistance to targeted therapy.
Boumahdi S; de Sauvage FJ
Nat Rev Drug Discov; 2020 Jan; 19(1):39-56. PubMed ID: 31601994
[TBL] [Abstract][Full Text] [Related]
11. [Melanoma therapeutic escape: the biomechanical track].
Lecacheur M; Girard CA; Deckert M; Tartare-Deckert S
Med Sci (Paris); 2020 Nov; 36(11):961-965. PubMed ID: 33151853
[No Abstract] [Full Text] [Related]
12. Fibroblasts Fuel Immune Escape in the Tumor Microenvironment.
De Jaeghere EA; Denys HG; De Wever O
Trends Cancer; 2019 Nov; 5(11):704-723. PubMed ID: 31735289
[TBL] [Abstract][Full Text] [Related]
13. Linking tumor glycolysis and immune evasion in cancer: Emerging concepts and therapeutic opportunities.
Ganapathy-Kanniappan S
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):212-220. PubMed ID: 28400131
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem cell-immune cell crosstalk in tumour progression.
Bayik D; Lathia JD
Nat Rev Cancer; 2021 Aug; 21(8):526-536. PubMed ID: 34103704
[TBL] [Abstract][Full Text] [Related]
15. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Jiang Y; Zhan H
Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
[TBL] [Abstract][Full Text] [Related]
16. Persister cell plasticity in tumour drug resistance.
McDonald PC; Dedhar S
Semin Cell Dev Biol; 2024 Mar; 156():1-10. PubMed ID: 37977107
[TBL] [Abstract][Full Text] [Related]
17. Ferroptosis, a subtle talk between immune system and cancer cells: To be or not to be?
Zhou Q; Tao C; Yuan J; Pan F; Wang R
Biomed Pharmacother; 2023 Sep; 165():115251. PubMed ID: 37523985
[TBL] [Abstract][Full Text] [Related]
18. Landscape of extracellular vesicles in the tumour microenvironment: Interactions with stromal cells and with non-cell components, and impacts on metabolic reprogramming, horizontal transfer of neoplastic traits, and the emergence of therapeutic resistance.
Zhang DX; Vu LT; Ismail NN; Le MTN; Grimson A
Semin Cancer Biol; 2021 Sep; 74():24-44. PubMed ID: 33545339
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-driven intratumor heterogeneity and immune evasion.
Terry S; Engelsen AST; Buart S; Elsayed WS; Venkatesh GH; Chouaib S
Cancer Lett; 2020 Nov; 492():1-10. PubMed ID: 32712233
[TBL] [Abstract][Full Text] [Related]
20. Iron metabolism: State of the art in hypoxic cancer cell biology.
Liu S; Cao X; Wang D; Zhu H
Arch Biochem Biophys; 2022 Jul; 723():109199. PubMed ID: 35398290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
